Sign in
Taking peoplePhase 2

SG301 injection for children with frequently relapsing or steroid-dependent nephrotic syndrome

Tests SG301 injections in children with relapsing or steroid-dependent nephrotic syndrome.

Key facts

Who runs it
Mao Jianhua
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
25 Aug 2025
Expected to end
9 Jul 2029
Type of study
Interventional
Treatments tested
  • SG301 Subcutaneous injection
Record updated
27 February 2026

Who can take part

The trial is looking for children aged 6 to 18 with nephrotic syndrome that responds to steroids but often comes back or needs steroids to stay controlled. It tests SG301 given as an injection under the skin.

Age
6 to 18 years
Sex
All sexes
Disease stage
Steroid-sensitive nephrotic syndrome with frequent relapses (FRNS) or steroid dependence (SDNS). Kidney function must be normal (eGFR ≥90 ml/min/1.73m²). After steroid treatment, urine protein must be low (morning urine protein <1+ or urine protein/creatinine <0.2 g/g (<20 mg/mmol)) for ≥3 days in a row.
Earlier treatment
No Tacrolimus, cyclosporine A, mycophenolate mofetil, belimumab, levamisole, azathioprine or cyclophosphamide in the past 2 months. No rituximab or obinutuzumab in the past 6 months. No earlier anti-CD38 treatment.
Biomarker or test result
Blood tests within 7 days before joining: hemoglobin >80 g/L, platelets >75×10⁹/L, neutrophils >1.5×10⁹/L. Prothrombin time/INR ≤1.5×ULN, unless caused by blood thinners.
Main reasons for not taking part
  • Nephrotic syndrome caused by another disease (such as IgA-related or lupus), or nephrotic syndrome that does not respond to steroids
  • Family history of nephrotic syndrome, chronic glomerulonephritis or uremia
  • Active hepatitis B or C, or HIV antibody-positive
  • Chronic or acute active infections, other autoimmune diseases, primary immunodeficiency or cancer
  • Live or weakened vaccine or major surgery within 4 weeks before the first dose
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • Aged 6 - 18 years
  • Steroid-sensitive nephrotic syndrome with frequent relapses (FRNS) or steroid dependence (SDNS)
  • Normal renal function: eGFR≥90 ml/min/1.73m²
  • After steroid treatment, morning urine protein<1 + or urine protein/creatinine<0.2 g/g (<20 mg/mmol) for ≥3 consecutive days
  • Within 7 days before enrollment, blood tests (without growth factors or transfusions) must meet: hemoglobin>80 g/L; platelets>75×10⁹/L; neutrophils>1.5×10⁹/L
  • Prothrombin time/INR≤1.5×ULN, unless due to anticoagulation
  • No Tacrolimus, cyclosporine A, mycophenolate mofetil, belimumab, levamisole, azathioprine, or cyclophosphamide in prior 2 months; no rituximab or obinutuzumab in prior 6 months

Who cannot take part

  • Prior anti - cluster of differentiation 38 (CD38) treatment
  • Live/attenuated vaccine receipt or major surgery (non - diagnostic) within 4 weeks before first dose
  • Family history of nephrotic syndrome, chronic glomerulonephritis, or uremia
  • HBsAg or HBcAb positive with Hepatitis B virus DNA above the lower limit of normal; Hepatitis C virus antibody - positive with Hepatitis C virus RNA positive; HIV antibody - positive
  • Chronic active infections (e.g., Epstein-Barr Virus, Cytomegalovirus, tuberculosis) that may worsen with steroids/ immunosuppressants
  • Acute active infection (excluding onychomycosis) requiring systemic antibiotics/antivirals
  • Secondary nephrotic syndrome (e.g.,immunoglobulin A - associated, lupus nephritis); steroid - resistant nephrotic syndrome (SRNS)
  • Other autoimmune diseases, primary immunodeficiency, or malignancy
  • Alanine aminotransferase >2×ULN or total bilirubin>2×ULN with a sustained increase for 2 weeks

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Nephrotic syndrome

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is an open - label study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of SG301 Subcutaneous injection in children with frequently relapsing or steroid - dependent nephrotic syndrome.

The group in the trial

  • SG301 Subcutaneous injectionTreatment being tested

    full - dose prednisone (60 mg/m²/day, up to 80 mg) for remission induction. After 3 days of negative urine protein, start SG301 Subcutaneous injection with steroid tapering. Taper prednisolone to 60 mg/m² (max 80 mg) every other day, reducing by 1/6 every 2 weeks, and stop after 3 months.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Clinical Study to Evaluate the Initial Efficacy and Safety of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome
Plain-language title
SG301 injection for children with frequently relapsing or steroid-dependent nephrotic syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07087314, who can take part
Record updated
27 February 2026